stockrow
Monday 9 November 2026
Export CABA’s income statement to Excel — free account
Cabaletta Bio, Inc.
CABA- EPS
- +53.4%
- Free cash flow
- −35.7%
Quarter to June 2026, against a year earlier
1.30
0.02
+1.56%
Follow CABA
Alert me
Cabaletta Bio, Inc. (CABA) P/E ratio
Cabaletta Bio, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACIU AC Immune compare | n/m |
| GLSI Greenwich LifeSciences, Inc. compare | n/m |
| FATE Fate Therapeutics, Inc. compare | n/m |
| CABA Cabaletta Bio, Inc. | n/m |
| ABEO Abeona Therapeutics Inc. compare | n/m |
| IMRX Immuneering Corporation compare | n/m |
| SLGL Sol-Gel Technologies Ltd. compare | n/m |
| KRRO Korro Bio, Inc. compare | n/m |
| VNDA Vanda Pharmaceuticals Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)